Form 4 for GYRE GYRE THERAPEUTICS, INC.

Accepted 2025-02-06 00:00:00 ET · period of report 2025-02-04 · accession 0001140361-25-003426 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MTI	2025-02-06	2025-02-04+	GYRE	Ma Songjiang	Pres, Dir	S - Sale	$12.01	-4,000	2.88M	-0.1%	-$48.0K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2025-02-05	S	D	20	$12.84	2,883,138	I By Spouse	—	—	(F4) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $12.835 to $12.84. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
2	Common	Common Stock	2025-02-04	S	D	2,000	$11.62	2,885,138	I By Spouse	—	—	(F2) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.33 to $11.87. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
3	Common	Common Stock	2025-02-05	S	D	1,980	$12.39	2,883,158	I By Spouse	—	—	(F3) The price reported represents the weighted average sale price per share. The shares were sold in multiple transactions at prices ranging from $11.82 to $12.81. Upon request by the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.